©
Shutterstock
Image courtesy of Shutterstock
The investment will support the PRECISION Panc project which aims to develop personalised treatments for pancreatic cancer patients, improving the options and outcomes for a disease where survival rates have remained stubbornly low.
The work is being jointly led by researchers from the Cancer Research UK/Medical Research Council Oxford Institute for Radiation Oncology, the University of Glasgow, the Cancer Research UK Beatson Institute, the Cancer Research UK Glasgow Clinical Trials Unit, the University of Manchester, the Cancer Research UK Manchester Institute, the Institute for Cancer Research, and the Cancer Research UK Cambridge Institute. The Oxford team will be investigating the potential role of radiotherapy in personalised therapy.